237 related articles for article (PubMed ID: 27932263)
1. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.
Kabiri M; Chhatwal J; Donohue JM; Roberts MS; James AE; Dunn MA; Gellad WF
Healthc (Amst); 2017 Sep; 5(3):105-111. PubMed ID: 27932263
[TBL] [Abstract][Full Text] [Related]
2. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Chidi AP; Bryce CL; Donohue JM; Fine MJ; Landsittel DP; Myaskovsky L; Rogal SS; Switzer GE; Tsung A; Smith KJ
Value Health; 2016 Jun; 19(4):326-34. PubMed ID: 27325324
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective.
Menzin J; White LA; Nichols C; Deniz B
BMC Health Serv Res; 2012 Dec; 12():459. PubMed ID: 23241078
[TBL] [Abstract][Full Text] [Related]
4. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
5. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
6. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.
Herink MC; Geddes J; Vo K; Zaman A; Hartung DM
J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560
[No Abstract] [Full Text] [Related]
7. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
8. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
9. Treating Medicaid patients with hepatitis C: clinical and economic impact.
Younossi Z; Gordon SC; Ahmed A; Dieterich D; Saab S; Beckerman R
Am J Manag Care; 2017 Feb; 23(2):107-112. PubMed ID: 28245654
[TBL] [Abstract][Full Text] [Related]
10. Overview of Comprehensive Hepatitis C Virus Medication Management in a State Medicaid Program.
Lavitas P; Tesell M; Hydery T; Greenwood BC; Price M; Lenz K; Jeffrey P
J Manag Care Spec Pharm; 2016 Oct; 22(10):1161-6. PubMed ID: 27668564
[TBL] [Abstract][Full Text] [Related]
11. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
[TBL] [Abstract][Full Text] [Related]
12. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
[TBL] [Abstract][Full Text] [Related]
13. Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage.
Wahid NA; Lee J; Kaplan A; Fortune BE; Safford MM; Brown RS; Rosenblatt R
Liver Transpl; 2021 Dec; 27(12):1723-1732. PubMed ID: 34118120
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.
Leidner AJ; Chesson HW; Xu F; Ward JW; Spradling PR; Holmberg SD
Hepatology; 2015 Jun; 61(6):1860-9. PubMed ID: 25677072
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
Mantravadi S
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
[No Abstract] [Full Text] [Related]
17. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
18. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.
Nguyen JT; Rich JD; Brockmann BW; Vohr F; Spaulding A; Montague BT
J Urban Health; 2015 Aug; 92(4):635-49. PubMed ID: 25828149
[TBL] [Abstract][Full Text] [Related]
19. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of total state coverage for hepatitis C medications.
Padula WV; Levin JS; Lee J; Anderson GF
Am J Manag Care; 2021 May; 27(5):e171-e177. PubMed ID: 34002969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
